Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎
A chronic disease that damages the small bile ducts within the liver.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 173
- cities
- 51
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 33% of the world's English-language research papers on primary biliary cholangitis, 2021–2025 (22% in 2016–2020), and 26% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
173 hospitals in 51 cities
Order: papers led on primary biliary cholangitis, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 1 papers or 1 trial on primary biliary cholangitis, or was a site in 1 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens primary biliary cholangitis in that city. 41 more cities are in the menu below.
- 22 papers led
- 17 papers led
- 17 papers led
- 12 papers led
- 12 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 38
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 36 papers led6 hospitals
- 24 papers led1 hospital
- 19 papers led3 hospitals
- 17 papers led1 hospital
- 14 papers led3 hospitals
- 13 papers led2 hospitals
- 12 papers led2 hospitals
- 9 papers led2 hospitals
- 7 papers led1 hospital
- 7 papers led5 hospitals
- 7 papers led4 hospitals
- 6 papers led1 hospital
- 5 papers led1 hospital
- 5 papers led2 hospitals
- 4 papers led2 hospitals
- 4 papers led3 hospitals
- 4 papers led2 hospitals
- 4 papers led3 hospitals
- 4 papers led2 hospitals
- 4 papers led2 hospitals
- 3 papers led2 hospitals
- 3 papers led2 hospitals
- 3 papers led2 hospitals
- 3 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 1 paper led1 hospital
- 1 paper led1 hospital
- 0 papers led0 hospitals
- 0 papers led0 hospitals
open trials on primary biliary cholangitis in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 13 Nov 2026, with at least one listed hospital as lead sponsor or site, and at least one listed hospital's site marked open. 9 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingBiochemical Response and Clinical Outcomes in Patients With PBC
- Phase
- Not given
- Started
- 2026-02
- Registry
- NCT07449793
Age 18 years to 85 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingPBC Long-term Outcomes Study
- Phase
- Not given
- Started
- 2025-05
- Registry
- NCT07149675
Age not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingA Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07282353
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingFIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07296458
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 1 listed hospital as study siteGuangzhou, Xi'an
- RecruitingFenofibrate in Primary Biliary Cholangitis: a Real World Study
- Phase
- Phase 3
- Started
- 2024-01
- Registry
- NCT06755151
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingFenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study
- Phase
- Phase 3
- Started
- 2024-01
- Registry
- NCT06755541
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingFenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- Phase
- Phase 2/Phase 3
- Started
- 2023-02
- Registry
- NCT05749822
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan’an, Zhengzhou
- RecruitingFenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
- Phase
- Phase 3
- Started
- 2023-02
- Registry
- NCT05751967
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an
- RecruitingSeladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- Phase
- Phase 3
- Started
- 2023-09
- Registry
- NCT06051617
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingClinical Research of Tapering UDCA in PBC Patients With a Complete Response
- Phase
- Phase 4
- Started
- 2020-01
- Registry
- NCT04650243
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingFenofibrate in Patients With Primary Biliary Cholangitis (PBC)
- Phase
- Phase 2/Phase 3
- Started
- 2017-04
- Registry
- NCT06365424
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
Where these numbers come from
Papers
300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 13 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.